94 related articles for article (PubMed ID: 11248422)
41. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
42. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
[TBL] [Abstract][Full Text] [Related]
43. Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.
Scala S; Budillon A; Zhan Z; Cho-Chung YS; Jefferson J; Tsokos M; Bates SE
J Clin Invest; 1995 Aug; 96(2):1026-34. PubMed ID: 7543490
[TBL] [Abstract][Full Text] [Related]
44. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells.
Abe T; Gotoh S; Higashi K
Biochim Biophys Acta; 1999 Apr; 1445(1):123-33. PubMed ID: 10209264
[TBL] [Abstract][Full Text] [Related]
45. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
46. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells.
Srivastava RK; Srivastava AR; Park YG; Agrawal S; Cho-Chung YS
Breast Cancer Res Treat; 1998 May; 49(2):97-107. PubMed ID: 9696392
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
48. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
49. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
[TBL] [Abstract][Full Text] [Related]
50. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
51. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
[TBL] [Abstract][Full Text] [Related]
52. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
[TBL] [Abstract][Full Text] [Related]
53. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
54. Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment.
Raaphorst GP; Wang G; Stewart D; Ng CE
Int J Radiat Biol; 1996 May; 69(5):623-31. PubMed ID: 8648250
[TBL] [Abstract][Full Text] [Related]
55. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIalpha regulatory subunit.
Neary CL; Cho-Chung YS
Oncogene; 2001 Nov; 20(55):8019-24. PubMed ID: 11753685
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of CCDC69 activates p14
Cui L; Zhou F; Chen C; Wang CC
J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135
[TBL] [Abstract][Full Text] [Related]
57. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex.
Robinson-White A; Meoli E; Stergiopoulos S; Horvath A; Boikos S; Bossis I; Stratakis CA
J Clin Endocrinol Metab; 2006 Jun; 91(6):2380-8. PubMed ID: 16569736
[TBL] [Abstract][Full Text] [Related]
58. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
59. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
Zheng L; Li L; Lu Y; Jiang F; Yang XA
Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
[TBL] [Abstract][Full Text] [Related]
60. [Killing effect of adenovirus mediated fusion gene cytosine and deaminase uracil phosphoribosyl transferase directed by glutathione S-transferase P1 promoter on cisplatin-resistant ovarian cancer cells in vitro].
Cai LQ; Li M; Lu S; Wang HB; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):478-81. PubMed ID: 15347473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
